Cargando…

Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer

BACKGROUND: Prior studies suggest lymphopenia, systemic immune-inflammatory index, and tumor response all impact clinical outcomes in Stage III NSCLC. We hypothesized that tumor response after CRT would be associated with hematologic metrics and might predict clinical outcomes. MATERIALS AND METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deck, Jared, Hartley, Marissa, Akhter, Mohammad, Wang, Dongliang, Bogart, Jeffrey A, Mix, Michael D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204762/ https://www.ncbi.nlm.nih.gov/pubmed/37228390 http://dx.doi.org/10.2147/LCTT.S386344

Ejemplares similares

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Severe radiation-induced lymphopenia during concurrent chemoradiotherapy for stage III non-small cell lung cancer: external validation of two prediction models
por: van Rossum, Peter S. N., et al.
Publicado: (2023)

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
por: Sher, David J.
Publicado: (2017)

Prediction and clinical impact of delayed lymphopenia after chemoradiotherapy in locally advanced non-small cell lung cancer
por: Kang, Byung-Hee, et al.
Publicado: (2022)

Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer
por: Newman, Neil B., et al.
Publicado: (2020)

Clinical outcomes following advanced respiratory motion management (respiratory gating or dynamic tumor tracking) with stereotactic body radiation therapy for stage I non-small-cell lung cancer
por: Aridgides, Paul, et al.
Publicado: (2018)

Association between treatment-related lymphopenia and survival in glioblastoma patients following postoperative chemoradiotherapy
por: Mapelli, Roberto, et al.
Publicado: (2021)

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer
por: Kang, Ki Mun, et al.
Publicado: (2012)

Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
por: Conibear, John
Publicado: (2020)

Hypofractionated concurrent chemoradiotherapy related lymphopenia and its association with survival in locally advanced non-small cell lung cancer patients
por: Liu, FangJie, et al.
Publicado: (2022)

Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer
por: Mix, Michael, et al.
Publicado: (2019)

Efficacy and tolerability of stereotactic body radiotherapy for lung metastases in three patients with pediatric malignancies
por: Deck, Jared, et al.
Publicado: (2019)

Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer
por: Abacioglu, Ufuk, et al.
Publicado: (2005)

Stereotactic body radiation therapy mitigates radiation induced lymphopenia in early stage non-small cell lung cancer
por: McLaughlin, Mark F., et al.
Publicado: (2020)

Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study
por: Miyawaki, Eriko, et al.
Publicado: (2022)

Chemoradiotherapy versus radiotherapy alone following induction chemotherapy for elderly patients with stage III lung cancer
por: Kim, Dong-Yun, et al.
Publicado: (2019)

Real‐world outcomes of chemoradiotherapy for unresectable Stage III non‐small cell lung cancer: The SOLUTION study
por: Horinouchi, Hidehito, et al.
Publicado: (2020)

Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy
por: Takahara, Yutaka, et al.
Publicado: (2022)

Neoadjuvant Chemoradiotherapy vesus Chemotherapy alone Followed by Surgery for Resectable Stage III Non-Small-Cell Lung Cancer: a Meta-Analysis
por: Guo, Shan xian, et al.
Publicado: (2016)

Consolidation chemotherapy improves progression-free survival in stage III small-cell lung cancer following concurrent chemoradiotherapy: a retrospective study
por: Chen, Xin-Ru, et al.
Publicado: (2016)

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
por: Jing, Wang, et al.
Publicado: (2022)

Prophylactic cranial irradiation-related lymphopenia affects survival in patients with limited-stage small cell lung cancer
por: Fan, Xinyu, et al.
Publicado: (2023)

Lymphopenia, Lymphopenia-Induced Proliferation, and Autoimmunity
por: Sheu, Ting-Ting, et al.
Publicado: (2021)

The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy
por: Koo, Tae Ryool, et al.
Publicado: (2014)

Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer
por: Taugner, Julian, et al.
Publicado: (2020)

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
por: Huang, Yiqing, et al.
Publicado: (2022)

Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
por: Tang, Shi, et al.
Publicado: (2023)

Bone marrow dosimetric analysis of lymphopenia in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy
por: Wang, Qian, et al.
Publicado: (2021)

Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy
por: Cheng, Xingyuan, et al.
Publicado: (2023)

Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities
por: Kobayashi, Haruki, et al.
Publicado: (2021)

Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis
por: Chang, Xiu-Jun, et al.
Publicado: (2016)

Utility of Restaging MRI Following Neoadjuvant Chemoradiotherapy for Stage II-III Rectal Adenocarcinoma
por: Aryan, Mahmoud, et al.
Publicado: (2021)

Early tumor shrinkage served as a prognostic factor for patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy
por: Wei, Min, et al.
Publicado: (2018)

Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer
por: Eberst, Guillaume, et al.
Publicado: (2022)

A retrospective study of shrinking field radiation therapy during chemoradiotherapy in stage III non-small cell lung cancer
por: Jiang, Chenxue, et al.
Publicado: (2018)

Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)
por: Łazar-Poniatowska, Małgorzata, et al.
Publicado: (2021)

Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy
por: Zhou, Xi‐Lei, et al.
Publicado: (2019)

A biologically effective dose threshold for stereotactic body radiation therapy—can we put the issue to BED?
por: Mix, Michael, et al.
Publicado: (2020)

PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
por: Käsmann, Lukas, et al.
Publicado: (2023)

IDO1 Activity Predicts Lung Toxicity in Patients with Unresectable Stage III NSCLC and Chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tdi2hle190480oo19fpmdi5k3u